LRRK2 kinase inhibition to normalize lysosomal trafficking in Parkinson's disease
🧪 Overview
LRRK2 G2019S mutations cause autosomal dominant PD through hyperactivation that impairs vesicular trafficking via Rab GTPase phosphorylation. Multiple Phase 1 programs (DNL151, BIIB094) have demonstrated target engagement (>90% Rab10 dephosphorylation) with manageable safety profiles. Lung toxicity (lamellar body accumulation) represents a dose-limiting concern requiring intermittent dosing strategies. The biomarker (Rab10 phosphorylation) enables patient selection and response monitoring.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LRRK2
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRRK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |